Showing results (1611-1620 of 6,713) with videos related to
Sort By:
Pageof 672
Oncotargets and Therapy|August 4, 2022
Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case ReportYunYu Lin, Yan Lei, LinWei Li, et al.Oncotargets and Therapy|May 23, 2020
miR-145 Inhibits Th9 Cell Differentiation by Suppressing Activation of the PI3K/Akt/mTOR/p70S6K/HIF-1α Pathway in Malignant Ascites from Liver CancerYou-Yi Huang, Hai-Xing Jiang, Qiu-Yue Shi, et al.Oncotargets and Therapy|May 23, 2020
GPR30 Promotes the Phenotypic Switching of Vascular Smooth Muscle Cells via Activating the AKT and ERK PathwaysBinshan Zha, Peng Qiu, Chenxin Zhang, et al.Oncotargets and Therapy|May 23, 2020
The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric CancerWanjun Zhang, Junwei Niu, Yongcheng Ma, et al.Oncotargets and Therapy|May 23, 2020
The Role of DLLs in Cancer: A Novel Therapeutic TargetMeng-Xi Xiu, Yuan-Meng Liu, Bo-Hai KuangOncotargets and Therapy|May 7, 2021
Alectinib for Miliary Lung Metastasis in ALK-Positive Lung AdenocarcinomaHironori Satoh, Yusuke Okuma, Jumpei Kashima, et al.Oncotargets and Therapy|May 21, 2020
Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic LandscapeMary E Hall, Heather L Huelster, Amy N Luckenbaugh, et al.Oncotargets and Therapy|May 3, 2021
EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case ReportZhiqin Lu, Xia Wang, Yuxi Luo, et al.Oncotargets and Therapy|June 12, 2020
Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case ReportRuixiao Wang, Jiayue Qin, Yafeng Fan, et al.Pageof 672